{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T06:24:03Z","timestamp":1787207043242,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bispecific antibodies (bsAbs) have rapidly emerged as one of the most promising therapeutic strategies in oncology because of their ability to simultaneously engage multiple molecular targets and enhance antitumor immunity. Although the number of publications has increased substantially, a comprehensive bibliometric characterization of the global research landscape and its developmental trajectory remain lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A bibliometric analysis was conducted using publications retrieved from the Web of Science Core Collection and Scopus from January 2014 to July 2026. After data standardization and deduplication, 5,929 eligible publications were included. CiteSpace, VOSviewer, and Bibliometrix were applied to evaluate publication trends, collaborations among countries, institutions, and authors, influential journals, keyword co-occurrence, citation bursts, and thematic evolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Global publications on bsAbs demonstrated sustained growth, particularly after 2018, reflecting rapidly increasing scientific interest. The USA and China contributed the largest research outputs, while several internationally collaborative institutions served as major research hubs. Highly cited journals and influential authors formed interconnected knowledge networks that characterized the scholarly structure of the field. Keyword clustering and timeline analyses revealed a progressive transition from antibody engineering and T-cell engager technologies toward clinical applications involving hematologic malignancies, solid tumors, combination immunotherapy, tumor microenvironment, and emerging therapeutic targets. Citation burst analyses further identified evolving research hotspots and highlighted increasing attention to translational and clinically oriented studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study reconstructs the global intellectual landscape and thematic evolution of oncology-oriented bsAb research. The findings provide a bibliometric overview of scientific development, identify current research frontiers, and may inform future collaboration, research prioritization, and investigation of next-generation bsAb therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1884087","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:28:53Z","timestamp":1787203733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global development of bispecific antibodies in oncology: a bibliometric analysis of geographic disparities, collaborative models, and emerging translational strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaotian","family":"Zhai","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs","place":["Beijing, China"]},{"name":"School of Pharmaceutical Sciences, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuona","family":"Rong","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs","place":["Beijing, China"]},{"name":"Department of Pharmacy, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Fu","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs","place":["Beijing, China"]},{"name":"School of Pharmaceutical Sciences, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlun","family":"Gu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongning","family":"Yao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Pang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs","place":["Beijing, China"]},{"name":"Department of Pharmacy, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology, Peking University First Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Clinical Pharmacology and Translation of Innovative Drugs","place":["Beijing, China"]},{"name":"School of Pharmaceutical Sciences, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.119.1.151","article-title":"Serologic demonstration of dual specificity of rabbit bivalent hybrid antibody","volume":"119","author":"Fudenberg","year":"1964","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the 'high-hanging fruit'","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.ccr-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/nejmoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/s0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102240","article-title":"The promise of bispecific antibodies: Clinical applications and challenges","volume":"99","author":"Lim","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105253","article-title":"Bispecific antibodies in solid tumors: An Italian Association of Medical Oncology (AIOM) multidisciplinary perspective on immunology and vaccination","volume":"221","author":"Lasagna","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"Surowka","year":"2021","journal-title":"MAbs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12248-019-0332-z","article-title":"A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART(\u00ae)","volume":"21","author":"Betts","year":"2019","journal-title":"AAPS J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100163","article-title":"Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule","volume":"1","author":"Berezhnoy","year":"2020","journal-title":"Cell Rep Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/jco.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: deLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/jco.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11192-014-1484-3","article-title":"Scientometrics and information retrieval: weak-links revitalized","volume":"102","author":"Mayr","year":"2015","journal-title":"Scientometrics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5539\/ass.v9n5p18","article-title":"A comparison between two main academic literature collections: web of science and scopus databases","volume":"9","author":"Aghaei Chadegani","year":"2013","journal-title":"Asian Soc Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbusres.2024.114760","article-title":"How to combine and clean bibliometric data and use bibliometric tools synergistically: Guidelines using metaverse research","volume":"182","author":"Lim","year":"2024","journal-title":"J Bus Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11192-020-03387-8","article-title":"A tale of two databases: the use of Web of Science and Scopus in academic papers","volume":"123","author":"Zhu","year":"2020","journal-title":"Scientometrics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202308915","article-title":"A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century","volume":"36","author":"Wang","year":"2024","journal-title":"Adv Mater"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acs.jnatprod.4c00081","article-title":"History and prospects of drug discovery and development collaboration between industry and academia","volume":"87","author":"Singh","year":"2024","journal-title":"J Nat Prod"},{"key":"B30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12915-020-00868-3","article-title":"Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis","volume":"18","author":"Cheng","year":"2020","journal-title":"BMC Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/224953a0","article-title":"Bradford's law and the bibliography of science","volume":"224","author":"Brookes","year":"1969","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2017-08-798322","article-title":"Bradford's law: Theory, empiricism and the gaps between","volume":"30","author":"Drott","year":"1981","journal-title":"Libr Trends"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/asi.23763","article-title":"Discrete power law with exponential cutoff and lotka's law","volume":"68","author":"Smolinsky","year":"2017","journal-title":"J Assoc Inf Sci Technol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"Walsh","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.108000","article-title":"From molecular engineering to clinical applications: The expanding role of bispecific antibodies in onco-immunology","volume":"221","author":"Borrelli","year":"2025","journal-title":"Pharmacol Res"},{"key":"B37","unstructured":"Synapse Global New Drug Intelligence Database"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/jco.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/nejmoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.cd-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"B44","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-023-00137-1","article-title":"Authorship and citation patterns of highly cited biomedical researchers: a cross-sectional study","volume":"8","author":"Perneger","year":"2023","journal-title":"Res Integr Peer Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s11192-024-05158-1","article-title":"The definition of highly cited researchers: the effect of different approaches on the empirical outcome","volume":"130","author":"Frietsch","year":"2025","journal-title":"Scientometrics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cac2.12400","article-title":"Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers","volume":"43","author":"Zou","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12325-025-03409-y","article-title":"Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed\/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion\/MoMMent","volume":"43","author":"Einsele","year":"2026","journal-title":"Adv Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/nejmoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/jco.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/nejmoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1884087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:28:54Z","timestamp":1787203734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1884087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1884087"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1884087","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1884087"}}